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ABSTRACT 
Objective: The objective of the present study was to synthesize novel benzopyrone derivatives with potential and safer anticonvulsant activity. 
Methods: New benzopyrone derivatives have been synthesized and characterized by spectral and elemental analysis. These compounds tested for 
anticonvulsant activity using the maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) screens (phase 1), which are the most 
widely employed seizure models for early identification of new anticonvulsant agents. Phase 2 including, neurotoxicity screening and quantitative 
determination of the median effective dose (ED50), median lethal dose (LD50) and protective index (PI) for the active compounds from phase 1. 
Results: Compound 12b possessed potent anticonvulsant activity with ED50 values of 94.75 and 70.7 mg/kg in the MES and scPTZ screens 
respectively, and had LD50 value of 2546 mg/kg after intraperitoneal injection to mice, which provide compound 12b with a wide protective index of 
26.87 and 36.01 for MES and scPTZ screens respectively compared to the reference drug Phenobarbital with PI of 12.16 and 20.08, respectively. In 
addition, compound 12b exhibited mild neurotoxicity at the maximum administrated dose (200 mg/kg).  
Conclusion: Compound 12b possessed broad spectrum activity for the treatment of all types of seizures, with a wide protective index compared to 
Phenobarbital. Consequently, compound 12b can be selected as a new bio candidate lead for further study.  
Keywords: Benzopyrone, Succinimide, 2-Iminothiazoline, Oxazine; Anticonvulsant. 
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
According to the International League Against Epilepsy (ILAE), 
epilepsy is defined as a brain disorder characterized by an enduring 
predisposition to generate epileptic seizures and by the 
neurobiological, cognitive, psychological and social consequences of 
this condition [1]. World health organization (WHO) estimated that 
approximately 50 million people currently live with epilepsy 
worldwide [2]. Many patients have seizures that are resistant to 
available medical therapies. Despite the introduction of new 
anticonvulsant drugs, all currently approved antiepileptic drugs 
have a dose-related toxicity and idiosyncratic side effects. As a 
result, intensive research efforts aim to find new, more effective and 
safer antiepileptic drugs. 
Surveying the literature reveals that, benzopyran-2-one derivatives 
are promising anticonvulsant candidates. Scoparone [3], osthole [4], 
esuprone [5] and 7-isopentenyloxycoumarin [6] have been found to 
possess moderate to strong anticonvulsant properties. In addition, 
succinimides [7] and 2-iminothiazolines [8, 9] ring systems have 
shown an anticonvulsant effect in pharmacological screening. Thus, 
the purpose of this work was to synthesize new derivatives of 3,4-
cyclopentene-8-methyl-2H-1-benzopyran-2-one 4hybridized at 7-
position with succinimides 7a-c and 2-iminothiazoline 9a,b, through 
oxy acetamido linker (fig. 1). The anticonvulsant activity of new 
compounds 7a-c and 9a, b was evaluated. 
Pyranobenzoxazines derivatives showed anticonvulsant activity in 
the preliminary pharmacological screening (fig. 2). Compounds 1 
and 3 showed anticonvulsant activity against seizures induced by 
strychnine sulphate [10] while compound 2 showed significant 







7  a RR1=CH2CH2
    b RR1=CH=CH






9  a R=C2H5, R1=CH








Heterocyclic ring systems  
Fig. 1: Design strategy and structures of the target compounds 
 
Consequently, the present work deals with the synthesis of novel 
derivatives of aryl pyrans benzoxazines 12 a, b (Scheme 2) aiming to 
produce potent and selective anticonvulsant candidates. 
MATERIALS AND METHODS 
Chemistry  
Melting points were determined by an open capillary tube method 
using Stuart SMP10 melting point apparatus and were uncorrected. 
Microanalysis was carried out at The Regional Center for Mycology 
and Biotechnology, Al-Azhar University. Infrared Spectra were 
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recorded as potassium bromide discs on Shimadzu FT-IR 8400S 
spectrophotometer (Shimadzu, Kyoto, Japan) and expressed in wave 
number (KBr) (cm-1). 1H-NMRspectra were recorded in δ scale given 
in ppm and performed on a JEOL ECA 300, 400 MHz spectrometer 




















Fig. 2: Linear and angular aryl pyranobenzoxazines with 
anticonvulsant activity 
 
Mass spectra were performed as EI at 70eV on Hewlett Packard 
Varian (Varian, Polo, USA) and Shimadzu Gas Chromatograph Mass 
spectrometer-QP 1000 EX and TSQ quantum (Thermo Electron 
Corporation) instrument prepared with a triple, quadruple mass 
detector (Thermo Finnigan) and an ESI source. TLC was carried out 
using Macherey-Nagel AlugramSil G/UV254 silica gel plates with 
fluorescent indicator UV254 and chloroform/methanol 9.5:0.5 as the 
eluting system and the spots were visualized at 366, 254 nm by UV 
Vilber Lourmat 77202 (Vilber, Marne La Vallee, France). Compounds 
4 and 5 were prepared according to reported procedure [12, 13]. 
General procedure for the synthesis of (3,4-cyclopentene-8-methyl-
2-oxo-2H-1-benzopyran-7-yloxy) acetic acid hydrazide (6) 
A solution of compound 5 (3.02 g, 0.01 mol) and hydrazine hydrate 
99 % (1.00 g, 0.98 ml, 0.02 mol) in absolute ethanol (10 ml) was 
refluxed for 2 h. The reaction mixture was cooled and the precipitate 
6 was filtered and dried (yield 87 %). The product was crystallized 
from 10 % acetic acid, mp above 300 °C. 1H-NMR (300 MHz)(DMSO-
d6) δ: 2.08-2.13 (m, 2H, CH2 cyclopentene), 2.28 (s, 3H, CH3), 2.74 (t, 
2H, J=7.1 Hz, CH2 cyclopentene), 3.05 (t, 2H, J=7.2 Hz, CH2 
cyclopentene), 4.32 (s, 2H, NH2), 4.78 (s, 2H, OCH2), 6.99 (d, 1H, J=8.4 
Hz, H-6 Ar), 7.41 (d, 1H, J=8.1 Hz, H-5 Ar), 10.21 (s, 1H, NH). IR (KBr) 
cm-1: 3460, 3417 (NH, NH2), 3045 (CH Ar), 2960, 2920 (CH 
aliphatic), 1728, 1689 (2 C=O), 1651, 1629, 1606, 1577 (NH, C=C). 
MS m/z: 288 (M+), 0.78 %. Anal. Calcd for C15H16N2O4; C, 62.49; H, 
5.59; N, 9.72. Found: C, 62.63; H, 5.64; N, 9.87. 
General procedure for the synthesis of compounds 7a-c 
To a solution of the acid hydrazide derivative 6 (2.88 g, 0.01 mol) in 
glacial acetic acid (15 ml), cyclic acid anhydrides (0.01 mol), namely, 
succinic, maleic and phthalic anhydride, was added and the mixture 
was heated under reflux for 9 h. The solvent was concentrated then 
the mixture was poured onto ice-water, the precipitated product 
was filtered, dried and crystallized from isopropanol. 
2-[(3,4-Cyclopentene-8-methyl-2-oxo-2H-1-benzopyran-7-
yl)oxy]-N-(2,5-dioxopyrrolidin-1-yl) acetamide (7a) 
Yield 76 %, mp 283-286 °C.1H-NMR (300 MHz) (DMSO-d6) δ: 2.08-
2.20 (m, 2H, CH2 cyclopentene), 2.29 (s, 3H, CH3), 2.74 (t, 2H, J=7.2 
Hz, CH2 cyclopentene), 2.80 (s, 4H, 2CH2 pyrrolidine), 3.06 (t, 2H, 
J=6.8 Hz, CH2 cyclopentene), 4.91 (s, 2H, OCH2), 7.02 (d, 1H, J=8.7 Hz, 
H-6 Ar), 7.43 (d, 1H, J=8.7 Hz, H-5 Ar), 10.69 (s, 1H, NH, D2O 
exchangable). IR (KBr) cm-1: 3344 (NH), 3095 (CH Ar), 2958, 2914 
(CH aliphatic), 1735, 1722, 1707 (4 C=O), 1649, 1629, 1608, 1577 
(NH, C=C). MS m/z: 370 (M+), 2.17 %. Anal. Calcd for C19H18N2O6; C, 
61.62; H, 4.90; N, 7.56. Found: C, 61.84; H, 4.94; N, 7.67. 
2-[(3,4-Cyclopentene-8-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]-
N-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) acetamide (7b) 
Yield 79 %, mp 245-247 °C.1H-NMR (300 MHz) (DMSO-d6) δ: 2.09-
2.16 (m, 2H, CH2 cyclopentene), 2.30 (s, 3H, CH3), 2.75 (t, 2H, J=6.8 
Hz, CH2 cyclopentene), 3.06 (t, 2H, J=7.1 Hz, CH2 cyclopentene), 4.93 
(s, 2H, OCH2), 7.01 (d, 1H, J=8.7 Hz, H-6 Ar), 7.20 (s, 2H, CH=CH 
pyrrole), 7.44 (d, 1H, J=8.7 Hz, H-5 Ar), 10.66 (s, 1H, NH, D2O 
exchangable). IR (KBr) cm-1: 3344 (NH), 3076 (CH Ar), 2958, 2929 
(CH aliphatic), 1730, 1725, 1705 (4 C=O), 1631, 1610, 1575, 1550 
(NH, C=C). MS m/z: 368 (M+), 8.05 %. Anal. Calcd for C19H16N2O6; C, 
61.95; H, 4.38; N, 7.61. Found: C, 62.12; H, 4.45; N, 7.74. 
2-[(3,4-Cyclopentene-8-methyl-2-oxo-2H-1-benzopyran-7-yl) 
oxy]-N-(1,3-dioxoisoindolin-2-yl) acetamide (7c) 
Yield 81 %, mp 290-291 °C.1H-NMR (300 MHz) (DMSO-d6) δ: 2.09-
2.14 (m, 2H, CH2 cyclopentene), 2.32 (s, 3H, CH3), 2.75 (t, 2H, J=7.4 
Hz, CH2 cyclopentene), 3.07 (t, 2H, J=7.4 Hz, CH2 cyclopentene), 5.00 
(s, 2H, OCH2), 7.06 (d, 1H, J=9 Hz, H-6 Ar), 7.46 (d, 1H, J=8.7 Hz, H-5 
Ar), 7.93-8.00 (m, 4H, Ar-H), 10.92 (s, 1H, NH, D2O exchangable). IR 
(KBr) cm-1: 3363 (NH), 3095, 3066 (CH Ar), 2968, 2958 (CH 
aliphatic), 1788, 1735, 1712, 1678 (4 C=O), 1649, 1631, 1610, 1577 
(NH, C=C). MS m/z: 418 (M+), 35.15 %. Anal. Calcd for C23H18N2O6; C, 
66.40; H, 4.34; N, 6.70. Found: C, 66.17; H, 4.36; N, 6.82. 
General procedure for the synthesis of compounds (8a, b) 
To a solution of the acid hydrazide derivative 6 (2.88 g, 0.01 mol) in 
absolute ethanol (40 ml), the appropriately substituted 
isothiocyanate (0.01 mol) was added and the mixture was refluxed 
while stirring for 12 h. the separated solid was filtered, washed with 
ether and dried. The crude product was crystallized from ethanol. 
1-(3,4-Cyclopentene-8-methyl-2-oxo-2H-1-benzopyran-7-
yloxy)acetyl-4-ethyl thiosemicarbazide (8a) 
Yield 80 %, mp 211-212 °C. 1H-NMR (300 MHz) (DMSO-d6) δ: 1.07 (t, 
3H, J=7.2 Hz, CH2CH3), 2.08-2.13 (m, 2H, CH2 cyclopentene), 2.29 (s, 
3H, CH3), 2.74 (t, 2H, J=7.2 Hz, CH2 cyclopentene), 3.05 (t, 2H, J=6.9 
Hz, CH2 cyclopentene), 3.46 (q, 2H, J=6.6 Hz, CH2CH3), 4.74 (s, 2H, 
OCH2), 6.99 (d, 1H, J=8.4 Hz, H-6 Ar), 7.41 (d, 1H, J=8.7 Hz, H-5 Ar), 
7.96 (s, 1H, NH, exchanged with D2O), 9.20 (s, 1H, NH, exchanged 
with D2O), 9.96 (s, 1H, NH, exchanged with D2O). IR (KBr) cm-1: 3416, 
3324, 3238 (3 NH), 3065 (CH Ar), 2965, 2925 (CH aliphatic), 1713, 
1666 (2 C=O), 1607, 1574, 1539 (NH, C=C), 1264 (C=S). MS m/z: 375 
(M+), 0.45 %. Anal. Calcd for C18H21N3O4S; C, 57.58; H, 5.64; N, 11.19. 
Found: C, 57.76; H, 5.71; N, 11.34. 
1-(3,4-Cyclopentene-8-methyl-2-oxo-2H-1-benzopyran-7-
yloxy)acetyl-4-phenyl thiosemicarbazide (8b) 
Yield 85 %, mp 255-256 °C. 1H-NMR (300 MHz) (DMSO-d6) δ: 2.05-
2.12 (m, 2H, CH2 cyclopentene), 2.27 (s, 3H, CH3), 2.70 (t, 2H, J=7.2 
Hz, CH2 cyclopentene), 2.99 (t, 2H, J=7.8 Hz, CH2 cyclopentene), 4.78 
(s, 2H, OCH2), 5.17 (s, 2H, 2NH), 6.98 (d, 1H, J=8.4 Hz, H-6 Ar), 6.99 
(d, 1H, J=8.7 Hz, H-5 Ar), 7.32-7.53 (m, 5H, Ar-H), 10.21 (s, 1H, NH). 
IR (KBr) cm-1: 3446, 3417, 3147 (3 NH), 3037 (CH Ar), 2920 (CH 
aliphatic), 1726, 1674 (2 C=O), 1651, 1606, 1606, 1571 (NH, C=C), 
1282 (C=S). MS m/z: 423 (M+), 0.58 %. Anal. Calcd for C22H21N3O4S; 
C, 62.40; H, 5.00; N, 9.92. Found: C, 62.57; H, 5.13; N, 9.97. 
General procedure for the synthesis of compounds (9a,b) 
A mixture of acyl thiosemicarbazide derivative 8a,b (1 mmol) and 
methyl phenacyl bromide (0.32 g, 1.5 mmol) and anhydrous sodium 
acetate (0.1 g, 1.2 mmol) in absolute ethanol (10 ml) was refluxed 
for 24 h. The solvent was distilled under vacuum, and the residue 
was extracted with chloroform. The extract was washed with water, 
filtered over anhydrous sodium sulfate and evaporated under 




Yield 67 %, mp 219-221 °C. 1H-NMR (300 MHz) (CDCl3) δ: 1.32 (t, 
3H, J=7.2 Hz, CH2CH3), 2.13-2.23 (m, 2H, CH2 cyclopentene), 2.30 (s, 
3H, CH3 at C8), 2.41 (s, 3H, CH3 at C4′), 2.88 (t, 2H, J=7.4 Hz, CH2 
cyclopentene), 3.02 (t, 2H, J=7.8 Hz, CH2 cyclopentene), 4.08 (q, 2H, 
J=7.2 Hz, CH2CH3), 5.31 (s, 2H, OCH2), 7.05-7.08 (m, 3H, H-3′,5′ Ar 
and C5-H thiazoline), 7.23-7.27 (m, 2H, H-5 and H-6 Ar), 7.96 (d, 2H, 
J=8.1 Hz, H-2′,6′ Ar), 10.11 (s, 1H, NH, D2O exchangable). IR (KBr) 
cm-1: 3446 (NH), 3064, 3032 (CH Ar), 2983, 2968 (CH aliphatic), 
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1705, 1680 (2 C=O), 1610, 1606, 1573, 1550 (C=N, NH, C=C). MS 
m/z: 489(M+), 1.00 %. Anal. Calcd for C27H27N3O4S; C, 66.24; H, 5.56; 




Yield 71 %, mp 219-221 °C. 1H-NMR (300 MHz) (DMSO-d6) δ: 2.07-
2.12 (m, 2H, CH2 cyclopentene), 2.26 (s, 3H, CH3 at C8), 2.40 (s, 3H, 
CH3 at C4′), 2.74 (t, 2H, J=7.2 Hz, CH2 cyclopentene), 3.04 (t, 2H, J=7.4 
Hz, CH2 cyclopentene), 5.34 (s, 2H, OCH2), 6.98 (d, 1H, J=8.7 Hz, H-6 
Ar), 7.02 (s, 1H, C5-H thiazoline), 7.29-7.99 (m, 10H, H-5 Ar, Ar-H), 
9.77 (s, 1H, NH, D2O exchangable). IR (KBr) cm-1: 3444 (NH), 3053, 
3026 (CH Ar), 2960, 2933 (CH aliphatic), 1693, 1680 (2 C=O), 1610, 
1600, 1571, 1560 (C=N, NH, C=C). MS m/z: 537(M+), 0.83 %. Anal. 
Calcd for C31H27N3O4S; C, 69.25; H, 5.06; N, 7.82. Found: C, 69.42; H, 
5.17; N, 7.98. 
Synthesis of 3,4-cyclopentene-7-hydroxy-8-methyl-6-nitro-2H-
1-benzopyran-2-one (10) 
A solution of nitric acid (6.3 ml, 0.1 mol) in sulfuric acid (6.5 ml) was 
added to a stirred solution of compound 4 (21.6 g, 0.1 mol) in 
sulfuric acid (38.6 ml) at such a rate as to keep the temperature 
below 5 (ice-salt bath cooling). The reaction mixture was poured 
into a stirred ice-water mixture, and a yellow precipitate was 
collected by filtration and dried to yield 24.0 g (92 %). The product 
was crystallized from ethanol, mp 194-195 °C. 1H-NMR (300 
MHz)(DMSO-d6) δ: 2.06-2.16 (m, 2H, CH2 cyclopentene), 2.25 (s, 3H, 
CH3), 2.76 (t, 2H, J=7.1 Hz, CH2 cyclopentene), 3.08 (t, 2H, J=7.2 Hz, 
CH2 cyclopentene), 8.05 (s, 1H, H-5 Ar), 10.94 (s, 1H, OH, exchanged 
with D2O). IR (KBr) cm-1: 3210 (OH), 3078 (CH Ar), 2957, 2854 (CH 
aliphatic), 1737 (C=O), 1620 (C=C), 1530, 1380 (NO2). MS m/z: 261 
(M+), 100 %. Anal. Calcd for C13H11NO5; C, 59.77; H, 4.24; N, 5.36. 
Found: C, 59.89; H, 4.31; N, 5.42. 
Synthesis of 6-amino-3, 4-cyclopentene-7-hydroxy-8-methyl-
2H-1-benzopyran-2-one (11) 
A solution of sodium dithionite (7 g, 0.04 mol) in water (30 ml) 
was quickly added to a solution of the nitro compound 10 (2.61 g, 
0.01 mol) in 30 % ammonium hydroxide solution (20 ml) and the 
reaction mixture was refluxed for 15 min. After cooling, the crude 
product was filtered off, washed and dried to yield 1.73 g (75 %). 
The product was crystallized from isopropanol, mp 222-223 °C. 
1H-NMR (300 MHz)(DMSO-d6) δ: 2.02-2.12 (m, 2H, CH2 
cyclopentene), 2.20 (s, 3H, CH3), 2.69 (t, 2H, J=7.1 Hz, CH2 
cyclopentene), 2.94 (t, 2H, J=7.4 Hz, CH2 cyclopentene), 6.16 (s, 2H, 
NH2, exchanged with D2O), 6.60 (s, 1H, H-5 Ar), 10.20 (s, 1H, OH, 
exchanged with D2O). IR (KBr) cm-1: 3375, 3315 (NH2), 3238 (OH), 
2957 (CH aliphatic), 1664 (C=O), 1577, 1503 (NH, C=C). MS m/z: 
231 (M+), 100 %. Anal. Calcd for C13H13NO3; C, 67.52; H, 5.67; N, 
6.06. Found: C, 67.76; H, 5.74; N, 6.19. 
General procedure for the synthesis of compounds (12a, b) 
To a solution of the amino derivative 11 (2.31 g, 0.01 mol) and 
sodium ethoxide (0.01 mol) in absolute ethanol (50 ml), the 
appropriate phenacyl bromide derivative (0.015 mol) was added 
and the solution was heated under reflux for 2 h. The reaction 
mixture was filtered, and the filtrate was concentrated then left to 
cool. The formed precipitate was filtered, washed, and dried. The 
crude product was crystallized from isopropanol. 
6,7-Cyclopentene-10-methyl-3-phenyl-2,8-dihydropyrano[5,6-
g]-1,4-benzoxazin-8-one (12a) 
Yield 75 %, mp 230-231 °C. 1H-NMR (400 MHz) (CDCl3) δ: 2.15-2.25 
(m, 2H, CH2 cyclopentene), 2.39 (s, 3H, CH3), 2.84 (t, 2H, J=9.3 Hz, 
CH2 cyclopentene), 3.09 (t, 2H, J=9.3 Hz, CH2 cyclopentene), 5.22 (s, 
2H, CH2 oxazine), 7.35 (s, 1H, H-5 Ar), 7.50 (d, 2H, J=6 Hz, H-2′,6′ Ar), 
7.78 (t, 1H, J=3.2 Hz, H-4′ Ar), 7.95 (d, 2H, J=6 Hz, H-3′,5′ Ar). IR 
(KBr) cm-1: 3058 (CH Ar), 2922, 2857 (CH aliphatic), 1716 (C=O), 
1621, 1571 (C=N, C=C). MS m/z: 331 (M+), 64.07 %. Anal. Calcd for 
C21H17NO3; C, 76.12; H, 5.17; N, 4.23. Found: C, 76.29; H, 5.21; N, 4.29. 
6,7-Cyclopentene-10-methyl-3-(4-methylphenyl)-2,8-dihydro-
pyrano-[5,6-g]-1,4-benzoxazin-8-one (12b) 
Yield 83 %, mp 210-211 °C. 1H-NMR (300 MHz) (CDCl3) δ: 2.19-2.26 
(m, 2H, CH2 cyclopentene), 2.34 (s, 3H, CH3), 2.43 (s, 3H, CH3), 2.92 (t, 
2H, J=7.1 Hz, CH2 cyclopentene), 3.07 (t, 2H, J=7.1 Hz, CH2 
cyclopentene), 5.16 (s, 2H, CH2 oxazine), 7.30 (d, 2H, J=8.1 Hz, H-3′,5′ 
Ar), 7.35 (s, 1H, H-5 Ar), 7.81 (d, 2H, J=7.8 Hz, H-2′,6′ Ar). IR (KBr) 
cm-1: 3050 (CH Ar), 2922 (CH aliphatic), 1715 (C=O), 1610 (C=N, 
C=C). MS m/z: 345 (M+), 100 %. Anal. Calcd for C22H19NO3; C, 76.50; 
H, 5.54; N, 4.06. Found: C, 76.68; H, 5.61; N, 4.17. 
Anticonvulsant screening 
All the compounds prepared herein were evaluated for their 
potential in vivo anticonvulsant activity against scPTZ and MES-
induced seizures in mice. The tested compounds were suspended in 
water and 1 % Tween 80 and administered to animals at a dose of 
100 mg/kg ip. Standard drug used was Phenobarbital sodium at the 
dose of 30 mg/kg. 
Adult albino mice weighing 20–25 g of both sexes (obtained from the 
animal house colony in the National Research) were used 
throughout this study. Animals were housed in groups of 6 and were 
allowed free access to food pellets (vit mix 1 %, mineral mix 4 %, 
corn oil 10 %, sucrose 20 %, cellulose 0.2 %, casein (95 %pure) 10.5 
%, starch 54.3 %) and water except for the short time that animals 
were removed from their cages for testing. All behavioral 
experiments were conducted during the period between 10:00 and 
13:00 with normal room light (12 h regular light/dark cycle) and 
temperature (22±18 OC). All Procedures involving animals and their 
care were performed after the Ethics Committee of the National 
Research Centre and in accordance with the recommendations for 
the proper care and use of laboratory animals, “Canadian Council on 
Animal Care Guidelines, 1984”. Additionally, all efforts were made to 
minimize animals suffering and to use only the number of animals 
necessary to produce reliable data. 
Subcutaneous pentylenetetrazole (scPTZ)-induced seizures test 
The tested compounds or the reference drug were given ip. to groups 
of 6 mice. Another group of 6 mice serves as a control. Sixty min after 
intraperitoneal administration, a dose of 85 mg/kg pentylenetetrazol 
(PTZ) was injected subcutaneously in a loose fold of skin on the back 
of the neck. Each animal is placed into an individual plastic cage for 
observation lasting 30 min. The incidence of tonic-clonic convulsions 
lasting for at least 5 seconds was recorded [14, 15]. Animal devoid of 
generalized convulsions were considered to be protected, and the 
results were represented as percentage protection, table 1. Besides 
that, the onset and duration of seizures were recorded, and statistics 
was done using chi-squared test with the aid of Graph pad Prism 
software, version 6 (inc., San Diego, USA). 
Maximal electroshock seizure (MES) test 
The procedure was carried out as described by Krall et al., [16] and 
Kitano et al., [17]. Electroshock was applied via ear-lip electrodes 
and generated by a stimulator (deliver an alternating 60 HZ current 
by Ugo Basile ECT Unit (Pulse generator 57800-001), the stimulus 
duration was 2.5 seconds, and the end point was tonic hind limb 
extension [18]. The maximum electroshock was determined. The 
drugs were administered orally 60 min before the test. The control 
animals were administered the vehicle. The mean threshold current 
for electroshock-induced tonic hind limb extensor seizure was 
calculated for each drug. The maximal seizures typically consist of a 
short period of initial tonic flexion and a prolonged period of tonic 
extension (especially of the hind limbs) followed by terminal clonus. 
The typical seizure lasts approximately 22 seconds failure to extend 
the hind limbs to an angle with trunk greater than 90o is defined as 
protection, table 1. The mean convulsion threshold of compounds 
under investigation as well as the standard error was calculated using 
chi-squared test with the aid of Graph pad Prism software, version 6 
(inc., San Diego, USA). 
Quantitative studies (phase 2) 
The most potent anticonvulsant compound 12b, from phase 1, were 
subjected to phase 2, which include neurotoxicity screen and 
Hamed et al. 
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quantitative determination of median effective dose (ED50), median 
lethal dose (LD50) and protective index (PI), as shown in table 3. 
Determination of the median effective dose (ED50) 
Anticonvulsant activity was expressed in terms of the median 
effective dose (ED50), that is, the dose of drug required to produce 
the biological responses in 50 % of animals [19]. Compound 12b, 
that gave the highest protection at a dose of 100 mg/kg were studied 
at different doses (50, 100 and 200 mg/kg) to calculate the ED50 
which was determined by log-linear regression analysis from the 
dose response curves to compare with ED50 of the reference drug 
Phenobarbital (10, 20 and 30 mg/kg), table 3. 
Determination of the neurotoxicity (Rotarod test) 
The neurotoxicity was assessed by rotarod test [20]. Prior to the 
experimental, male albino mice were placed on 3-centimeter rod 
(Ugo-Basile Accele. ROTA-ROD for mice, 7650) rotating at 6 rpm, in 
two training sessions that last 10 and 15 min respectively. The 
candidate under investigation was injected ip. (200 mg/kg in 1 % 
Tween 80), while Phenobarbital tested at 30 mg/kg. One hour later, 
the animals were again tested on the rotarod to assess the locomotor 
coordination and neurological deficit (e. g. ataxia, sedation, hyper-
excitability), which are reflected by the inability of the animal to 
maintain equilibrium on the rod after the administration of the 
selected candidate, table 3. The end point for minimal neurotoxicity 
assessment was reflected by the inability of mice to maintain their 
equilibrium on accelerating rotarod in each of the five trials. 
Determination of the median lethal dose (LD50) 
Male albino mice weight 20-25 g was divided into groups each of 8 
animals. Preliminary experiments were done to determine the 
minimal dose that kills all animals (LD100), and the maximal dose 
that fails to kill any animal. Several doses at equal logarithmic 
intervals were chosen in between these two doses, each dose was 
injected in a group of eight animals, the number of dead animals in 
each group after 24 h was recorded and LD50 was calculated 
according to the following formula using Spearman Karber method 
[21-23], Table 4. 
M = Xk+1/2 d–dr/N 
M = Log LD50, Xk = Log dose causing 100 % mortality, D = Logarithmic 
interval of doses, R = Sum of the number of dead animals at each of the 
individual dose levels, N = Number of animals at each of the dose level. 
RESULTS AND DISCUSSION 
Chemistry 
The general methods for the synthesis of target compounds 7a-c-
9a,b, and 12a,b are depicted in Schemes 1-2. The key intermediate 6 
was synthesized from 3, 4-cyclopentene-7-hydroxy-8-methyl-2H-1-
benzopyran-2-one 4 through etherification with ethyl chloroacetate 
to give the ether derivative5, followed by hydrazinolysis. 
The target imides 7a-c was obtained by condensation of the acid 
hydrazide 6 with the appropriate acid anhydrides, succinic, maleic and 
phthalic anhydride in glacial acetic acid, respectively. Acyl 
thiosemicarbazides 8a, b were prepared by refluxing solution of the 
acid hydrazide 6 in absolute ethanol with different isothiocyanates. 
While, 2-iminothiazoline derivatives 9a, b were prepared by refluxing 
acylthiosemicarbazides8a,b with methyl phenacyl bromide and 
anhydrous sodium acetate in absolute ethanol. 
The typical method for nitration of 3, 4-cyclopentene-7-hydroxy-8-
methyl-2H-1-benzopyran-2-one 4 involves the use of nitric acid and 
sulfuric acid, so-called ''mixed acid''. Sulfuric acid acts as a catalyst as 
well as an absorbent for water. 6-Nitrobenzopyran-2-one 10 was 
reduced to the corresponding amino compound 11 using sodium 
dithionite in ammonia for 15 min. Pyranobenzoxazin-8-one derivatives 
12a,b were synthesized in good yield by reaction of the amino compound 
11 with the appropriate phenacyl bromide derivatives in the presence of 
absolute ethanol and sodium ethoxide. Both the analytical and spectral 
data (IR, 1H-NMR, MS) of all the newly synthesized compounds were in 
























8  a  R=C2H5
    b  R=C6H5
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9 a R=C2H5









7  a RR1=CH2CH2
    b RR1=CH=CH



























Scheme 1: Reagents and conditions: (a) ethyl acetoacetate, dry acetone, reflux; (b) hydrazine hydrate 99 %, absolute ethanol, reflux; (c) 
acid anhydrides, glacial acetic acid, reflux; (d) isothiocyanates, absolute ethanol, reflux; (e) methylphenacyl bromide, anhydrous sodium 
acetate, absolute ethanol, reflux 
Hamed et al. 






















Scheme 2: Reagents and conditions: (a) HNO3/H2SO4; (b) NaS2O4; (c) phenacyl bromide derivatives, sodium ethoxide, absolute ethanol, reflux 
 
Biological evaluation 
Preliminary anticonvulsant screening (phase 1) 
The initial evaluation (phase 1) of anticonvulsant activity of the 
synthesized compounds included the maximal electroshock seizure 
(MES) and subcutaneous pentylenetetrazole (scPTZ) screens, which 
are the most widely employed seizure models for early identification 
of new anticonvulsant drugs. scPTZ test represents a valid model for 
generalized myoclonic seizures and also generalized seizures of the 
absence (petit mal) type and identify compounds that elevate 
seizure threshold [24]. On the other hand, the MES test is considered 
to be a predictor of likely therapeutic efficacy against generalized 
tonic-clonic seizures and identify clinical candidates that prevent 
seizure spread [25]. In the preliminary evaluation, the 
anticonvulsant activity was estimated at a dose of 100 mg/kg and 
the results are summarized in table 1. 
The results of MES screen revealed that:  
- Cyclization of the flexible thiosemicarbazide derivatives 7a,b 
into 2-iminothiazoline derivatives 8a,b, exhibited non-significant 
anticonvulsant activity. In addition cyclic imides 6a-c didn’t show 
activity. 
- Alkylation, the aryl group of pyranobenzoxazin-8-one 12b, gave 
potent anticonvulsant activity than the unsubstituted derivative 12a, 
which showed no significant activity, table 1. In addition, compound 
12b showed potent significantly anticonvulsant activity in both MES 
and scPTZ screens compared to the previously reported linear 
pyrano-benzoxazine derivative 1 due to alkylation of the aryl group. 
Also, compound 12b showed promising activity than angular 
pyrano-benzoxazine derivative 2, table 2. 
Concerning scPTZ screen, three parameters were considered, 
percentage protection for animals devoid of generalized seizures, 
beside that the onset and duration of clonic seizures were recorded 
for the unprotected animals. Compound 12b exhibited promising 
anticonvulsant activity (66.67 % protection). Moreover, compound 
12b delay the onset and decrease the time of clonic convulsion for 
the unprotected animals. 
Quantitative studies (phase 2) 
Based on the previous results from the preliminary study, 
compound 12b was selected for quantification of the 
pharmacological parameters, median effective dose (ED50), median 
lethal dose (LD50) and protective index (PI). Results of the 
quantitative and neurotoxicity screens, along with the data on the 
Phenobarbital, are reported in table 3.  
Compound 12b possessed broad spectrum activity with ED50 values 
of 94.75 and 70.7 mg/kg in the MES and scPTZ screens respectively, 
and had LD50 value of 2546 mg/kg after intraperitoneal injection to 
mice, which provide compound 12b with a wide protective index of 
26.87 and 36.01 for MES and scPTZ screens respectively compared 
to Phenobarbital with PI of 12.16 and 20.08, respectively. In 
addition, compound 12b showed mild motor impairment at the 
maximum administrated dose (200 mg/kg). 
 
Table 1: Anticonvulsant activity of compounds using maximal electroshocks (MES) and subcutaneous pentylenetetrazole (scPTZ)-induced 










Mean onset of clonic 
convulsion (min.)* 
Mean duration of clonic 
convulsion* (sec.) 
control 3.2±0.37 43.2 0 2.8±0.84 36±0.052 
Phenobarbital 7.4±0.40a ----- 83.3 8.4±0.19a 3.6±0.028a 
7a 3.2±0.20b 43.2 0 3.0±0.45b 31.2±0.040b 
7b 3.8±0.37b 51.4 0 3.4±0.49b 30±0.028b 
7c 3.3±0.21b 44.6 0 2.9±0.67b 28.8±0.036b 
8a 3.2±0.20b 43.2 0 3.1±0.50b 29.4±0.042b 
8b 3.4±0.24b 45.9 0 2.7±0.42b 30.6±0.032b 
9a 3.6±0.24b 48.6 16.67 3.1±0.42b 30.6±0.032b 
9b 3.4±0.40b 45.9 16.67 2.8±0.46b 31.8±0.040b 
12a 3.2±0.20b 43.2 0 3.2±0.52b 31.8±0.041b 
12b 6.0±0.68a 81.1 66.67 10.2±0.85a 11.4 ±0.028a 
* Values represent the mean±standard error of 6 animals for each group, (a) Values are statistically significant (p<0.05) from the control group by 
using one-way ANOVA (followed by Tukey’s Multiple Comparison tests)., (b) Values are statistically non-significant (p<0.05) from the Phenobarbital 
group., ** %Potency ( %potency from Phenobarbital)., *** %Protection (number of animals devoid of convulsion/number of animals used). 
 
Table 2: Comparison of the activity of the new active compound 12b to previously reported leads using maximal electroshock (MES) and 
subcutaneous pentylenetetrazole (scPTZ) screens 
Compound number MES %protection scPTZ %protection 
1[10] --- --- 
2[11] 50 --- 
12b (this work) 81 66.7 
Hamed et al. 
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Table 3: Quantitative studies for anticonvulsant activity (test drug administered ip.) 
PI LD50 mg/kg (mmol/kg) Neurotoxicity 
Stability time 
(Ratio) 
ED50 Compound number 
scPTZ MES scPTZ mg/kg (mmol/kg) MES mg/kg (mmol/kg) 
36.01 26.87 2546 (7.37) 4.783±0.1797 (2/6) 70.7 (0.21) 94.75 (0.27) 12b 
20.08 12.16 265 
(1.14) 





Median effective dose (ED50) determined in maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) screens.  
Values in neurotoxicity screen represent stability time/min, the mean±standard error of 6 animals for each group; statistics was done by one-way 
ANOVA. (Ratio=animals exhibited neurotoxicity/protected animals). Protective index (PI) = [median lethal dose (LD50)/median effective dose 
(ED50)]. (a) Data from reference [26]. 
 
Table 4: Median lethal dose (LD50) for the selected active compound 12b and phenobarbital using Spearman Karber method [21-23] 
Compound number Log dose Dose mice Compound number Log dose Dose mice 
12b 3.30 1995 0/8 Phenobarbital 2.27 186 0/8 
3.35 2238 2/8 2.32 209 1/8 
3.40 2500 4/8 2.37 234 2/8 
3.45 2818 5/8 2.42 263 4/8 
3.50 3160 8/8 2.47 295 5/8 
M=3.50+(0.5*0.05)-((0.05*19)/8)= 3.406 LD50 of 12b = antilog of M = 
2546 mg/kg 
2.52 333 8/8 
M=2.52+(0.5*0.05)-((0.05*20)/8)= 2.42 LD50 of Phenobarbital = antilog of 
M = 265 mg/kg 
 
CONCLUSION 
In summary, Compound 12b possessed broad spectrum activity for 
treatment of all types of seizures induced by MES and scPTZ, with 
ED50 values of 94.75 and 70.7 mg/kg respectively, and had LD50 
value of 2546 mg/kg after intraperitoneal injection to mice, which 
provide compound 12b with a wide protective index of 26.87 and 
36.01 for MES and scPTZ screens respectively compared to 
Phenobarbital with PI of 12.16 and 20.08, respectively. In addition, 
compound 12b exhibited mild neurotoxicity at the maximum 
administrated dose (200 mg/kg). Consequently, compound 12b can 
be selected as a new bio candidate lead for further study. 
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